

Pratiksha I Thakore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11101658/publications.pdf>

Version: 2024-02-01

18
papers

5,962
citations

567281

15
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

8268
citing authors

#	ARTICLE	IF	CITATIONS
1	Massively parallel phenotyping of coding variants in cancer with Perturb-seq. <i>Nature Biotechnology</i> , 2022, 40, 896-905.	17.5	44
2	Gut CD4+ T cell phenotypes are a continuum molded by microbes, not by TH archetypes. <i>Nature Immunology</i> , 2021, 22, 216-228.	14.5	116
3	Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. <i>Nature Genetics</i> , 2021, 53, 332-341.	21.4	112
4	Stem-like intestinal Th17 cells give rise to pathogenic effector T _H cells during autoimmunity. <i>Cell</i> , 2021, 184, 6281-6298.e23.	28.9	99
5	RNA-guided transcriptional silencing in vivo with <i>S. aureus</i> CRISPR-Cas9 repressors. <i>Nature Communications</i> , 2018, 9, 1674.	12.8	123
6	CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments. <i>Tissue Engineering - Part A</i> , 2017, 23, 738-749.	3.1	68
7	Editing the epigenome: technologies for programmable transcription and epigenetic modulation. <i>Nature Methods</i> , 2016, 13, 127-137.	19.0	341
8	In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. <i>Science</i> , 2016, 351, 403-407.	12.6	957
9	Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors. <i>Methods in Molecular Biology</i> , 2016, 1338, 71-88.	0.9	8
10	Enhanced MyoD-Induced Transdifferentiation to a Myogenic Lineage by Fusion to a Potent Transactivation Domain. <i>ACS Synthetic Biology</i> , 2015, 4, 689-699.	3.8	30
11	Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. <i>Nature Communications</i> , 2015, 6, 6244.	12.8	383
12	Genome Engineering for Therapeutic Applications. , 2015, , 27-43.		4
13	Correction of Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients Through Genomic Excision of Exon 51 by Zinc Finger Nucleases. <i>Molecular Therapy</i> , 2015, 23, 523-532.	8.2	100
14	Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. <i>Nature Biotechnology</i> , 2015, 33, 510-517.	17.5	1,487
15	Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. <i>Nature Methods</i> , 2015, 12, 1143-1149.	19.0	808
16	RNA-guided gene activation by CRISPR-Cas9-based transcription factors. <i>Nature Methods</i> , 2013, 10, 973-976.	19.0	1,105
17	Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients. <i>Molecular Therapy</i> , 2013, 21, 1718-1726.	8.2	160
18	Role of Pericellular Matrix in Mesenchymal Stem Cell Deformation during Chondrogenic Differentiation. <i>Cellular and Molecular Bioengineering</i> , 2010, 3, 387-397.	2.1	15